Notice2023-16105
National Center for Health Statistics, ICD-10 Coordination and Maintenance Committee
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 31, 2023
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
The Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, announces the following meeting of the ICD-10 Coordination and Maintenance (C&M) Committee. This meeting is open to the public, limited only by the number of audio lines available. Online Registration is required.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 145 (Monday, July 31, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 145 (Monday, July 31, 2023)]
[Notices]
[Pages 49465-49466]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-16105]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Center for Health Statistics, ICD-10 Coordination and
Maintenance Committee
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), National
Center for Health Statistics (NCHS), Classifications and Public Health
Data Standards Staff, announces the following meeting of the ICD-10
Coordination and Maintenance (C&M) Committee. This meeting is open to
the public, limited only by the number of audio lines available. Online
Registration is required.
DATES: The meeting will be held on September 12, 2023, from 9 a.m. to 5
p.m., EDT, and September 13, 2023, from 9 a.m. to 5 p.m., EDT.
ADDRESSES: This is a virtual meeting. Register in advance at <a href="https://cms.zoomgov.com/webinar/register/WN_lWLKuwKzQU6iJdvcDvXhdA">https://cms.zoomgov.com/webinar/register/WN_lWLKuwKzQU6iJdvcDvXhdA</a>. After
registering, you will receive a confirmation email containing
information about joining the meeting. Further information will be
provided on each of the respective web pages when it becomes available.
For CDC, NCHS: <a href="https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm">https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm</a>.
For the Centers for Medicare & Medicaid Services, Department of Health
and Human Services: <a href="https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials">https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials</a>.
FOR FURTHER INFORMATION CONTACT: Traci Ramirez, Medical Classification
Specialist, National Center for Health Statistics, Centers for Disease
Control and Prevention, 3311 Toledo Road, Hyattsville, Maryland 20782-
2064. Telephone: (301) 458-4454; Email: <a href="/cdn-cgi/l/email-protection#3d696f5c50544f58477d5e595e135a524b"><span class="__cf_email__" data-cfemail="cb9f99aaa6a2b9aeb18ba8afa8e5aca4bd">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Purpose: The ICD-10 Coordination and Maintenance (C&M) Committee is
a public forum for the presentation of proposed modifications to the
International Classification of Diseases, Tenth Revision, Clinical
Modification (CM) and ICD-10 Procedure Coding System (PCS).
Matters to be Considered: The tentative agenda will include
discussions on the ICD-10-CM and ICD-10-PCS topics listed below. Agenda
items are subject to change as priorities dictate. Please refer to the
posted agenda for updates one month prior to the meeting.
ICD-10-PCS Topics:
1. Administration of Iodine (131I) Apamistamab **
2. Irreversible Electroporation for Cardiac Ablation **
3. Computer-aided Anesthesia and Oxygen Delivery System ***
4. Sub-epidermal Moisture Sensor **
5. Insertion of Palladium-103 Radioactive Implant *
6. Implantation of Bone Void Filler ***
7. Section X Updates
8. Addenda and Key Updates *
* Request is for an April 1, 2024, implementation date.
** Request is for an April 1, 2024, implementation date, and the
requestor intends to submit a new technology add-on payment (NTAP)
application for FY 2025 consideration.
*** Requestor intends to submit an NTAP application for FY 2025
consideration.
Presentations for procedure code requests are conducted by both the
requestor and the Centers for Medicare & Medicaid Services (CMS) during
the C&M Committee meeting. Discussion from the requestor generally
focuses on the clinical issues for the procedure or technology,
followed by the proposed coding options from a CMS analyst. Topics
presented may also include requests for new procedure codes that relate
to a new technology add-on payment (NTAP) policy request.
CMS has modified the approach for presenting the new NTAP-related
ICD-10-PCS procedure code requests that involve the administration of a
therapeutic agent. For the September 12-13, 2023, ICD-10 C&M Committee
meeting, consistent with the requirements of section 1886(d)(5)(K)(iii)
of the Social Security Act, applicants submitted requests to create a
unique procedure code to describe the administration of a therapeutic
agent, such as the option to create a new code in Section X within the
ICD-10-PCS procedure code classification. CMS will initially display
only those meeting materials associated with the NTAP-related ICD-10-
PCS procedure code requests that involve the administration of a
therapeutic agent on the CMS website in August 2023 at: <a href="https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials">https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials</a>.
The NTAP-related ICD-10-PCS procedure code request that involves
the administration of a therapeutic agent is:
Administration of Iodine (131I) Apamistamab **
** Request is for an April 1, 2024, implementation date, and the
requestor intends to submit an NTAP application for FY 2025
consideration.
This topic will not be presented during the September 12-13, 2023,
meeting. CMS will solicit public comments regarding any clinical
questions or coding options included for this procedure code topic in
advance of the meeting continuing through the end of the respective
public comment periods. Members of the public should send any questions
or comments to the CMS mailbox at: <a href="/cdn-cgi/l/email-protection#7f363c3b2f0d101c1a1b0a0d1a3c101b1a2d1a0e0a1a0c0b3f1c120c5117170c51181009"><span class="__cf_email__" data-cfemail="08414b4c587a676b6d6c7d7a6d4b676c6d5a6d797d6d7b7c486b657b2660607b266f677e">[email protected]</span></a>.
CMS intends to post a question-and-answer document in advance of
the meeting to address any clinical or coding questions that members of
the public may have submitted. Following the conclusion of the meeting,
CMS will post an updated question-and-answer document to address any
additional clinical or coding questions that members of the public may
have submitted during the meeting that CMS was not able to address or
that were submitted after the meeting.
The NTAP-related ICD-10-PCS procedure code requests that do not
involve the administration of a therapeutic agent and all non-NTAP-
related procedure code requests will continue to be presented during
the virtual meeting on September 12, 2023, consistent with the standard
meeting process.
CMS will make all meeting materials and related documents available
at: <a href="https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials">https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials</a>. Any inquiries related to the procedure code topics scheduled
for the September 12-13, 2023, ICD-10 C&M Committee meeting that are
under consideration for
[[Page 49466]]
April 1, 2024, or October 1, 2024, implementation should be sent to the
CMS mailbox at: <a href="/cdn-cgi/l/email-protection#b5fcf6f1e5c7dad6d0d1c0c7d0f6dad1d0e7d0c4c0d0c6c1f5d6d8c69bddddc69bd2dac3"><span class="__cf_email__" data-cfemail="3178727561435e525455444354725e55546354404454424571525c421f5959421f565e47">[email protected]</span></a>.
ICD-10-CM Topics:
1. Abnormal Anti-cyclic Citrullinated Peptide Antibody and/or
Rheumatoid Factor Without Current or Prior Clinical Diagnosis of
Rheumatoid Arthritis
2. Adverse Effects of Immune Checkpoint Therapy
3. Anal Fistula
4. Baked Egg Tolerance
5. Baked Milk Tolerance
6. Duffy Phenotype
7. Flank Anatomical Specificity
8. Gulf War Illness
9. Hyperoxaluria
10. Injection Drug Use
11. Lymphoma in Remission
12. Post-exertional Malaise
13. Usher Syndrome
14. Addenda
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-16105 Filed 7-28-23; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 31, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.